TSXV:CLAS.H - Post by User
Post by
MinimumDamageon Mar 03, 2021 10:25pm
238 Views
Post# 32712128
Kalyteras progress forTreatment of acute and chronic pain
Kalyteras progress forTreatment of acute and chronic pain September 27, 2018
The commercial opportunity for Kalytera’s cannabinoid compound for treatment of pain is large. According to a 2016 report by Transparency Market Research, the global pain management therapeutics market is projected to reach USD $83 billion by 2024. Current treatments for pain mainly include non-steroidal anti-inflammatory drugs ("NSAIDs"), such as naproxen, for mild to moderate pain, and opioids, such as morphine, for moderate to severe and chronic pain. Kalytera believes that its product will be suitable for mild to severe pain, without the risks of respiratory suppression and dependence associated with opioid analgesics.
Full article :
https://www.globenewswire.com/news-release/2018/09/27/1577087/0/en/Kalytera-Announces-Progress-with-Cannabinoid-Based-Compound-for-Treatment-of-Acute-and-Chronic-Pain.html